Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine

WILMINGTON, Del.–(BUSINESS WIRE)–Full results from the positive Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine showed AstraZeneca’s BREZTRI Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) demonstrated statistically significant and clinically meaningful improvements in patients with uncontrolled asthma compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines: Symbicort (budesonide/formoterol fumarate or BFF, a standard … [Read more…]

Paradigm Signs Definitive Agreement to Be Acquired by Patient Square Capital

WALNUT CREEK, Calif.–(BUSINESS WIRE)–Paradigm (“Paradigm” or the “Company”), a specialty care management organization focused on delivering solutions that improve outcomes for individuals with complex injuries and diagnoses, today announced that it has entered into a definitive agreement to be acquired by Patient Square Capital (“Patient Square”), a leading health care investment firm. This planned investment … [Read more…]

Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / … [Read more…]

CHG Healthcare Brands Sweep ClearlyRated’s 2026 Best of Staffing Talent Award for Service Excellence

CompHealth, Weatherby Healthcare, and Global Medical Staffing earn top satisfaction scores, demonstrating CHG Healthcare’s industry‑leading commitment to provider experience and service excellence. MIDVALE, Utah–(BUSINESS WIRE)–CHG Healthcare, the nation’s largest physician staffing firm and industry leader in healthcare workforce success, announced today that three of its staffing brands — CompHealth, Weatherby Healthcare, and Global Medical Staffing … [Read more…]

The Emily Program Elevates the Conversation on Eating Disorders Through Educational Webinar Series

Expert-led live sessions to run during Eating Disorders Awareness Week ST. PAUL, Minn.–(BUSINESS WIRE)–The Emily Program, a national leader in eating disorder specialty care and behavioral health services, today announced its 2026 Learn with Emily webinar series. Designed for advocates, caregivers, and clinicians, the free, expert-led series explores insights on eating disorder care and recovery. … [Read more…]

Encora Therapeutics Receives FDA 510(k) Clearance for Encora X1™, a Breakthrough Wearable Device for Essential Tremor

BOSTON–(BUSINESS WIRE)–#activitiesofdailyliving—Encora Therapeutics, a leader in non-invasive neuromodulation technology, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Encora X1™. This clearance is supported by data from two clinical studies: a randomized, sham-controlled trial and a 90-day home-use study. Together, these studies demonstrated consistent improvements in tremor severity … [Read more…]

iProov Dynamic Liveness Is the First and Only Solution to Achieve CEN/TS 18099 High and Ingenium Level 4 for Injection Attack Detection

Establishes New Benchmark for High Identity Assurance Based on Accredited Testing of Industry Standard LONDON–(BUSINESS WIRE)–iProov, the world’s leading provider of science-based biometric identity verification solutions, today announced that its Dynamic Liveness technology is the first and only solution to successfully achieve an Ingenium Level 4 evaluation and the CEN/TS 18099 High technical specification for … [Read more…]

We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties

Galderma unveils We Are All Sculptra, a global campaign capturing the clinical performance of Sculptra® across nine diverse patient profiles and journeys, over two years1 Backed by over 25 years of clinical use, Sculptra continues to prove its versatility as a regenerative treatment that works across all three layers of the skin2-6 The campaign captures … [Read more…]

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

Approval expands PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2 SANTA CLARA, Calif.–(BUSINESS WIRE)–$A #BringGreatScienceToLife—Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian … [Read more…]